Antisense Therapeutics Ltd

What is Antisense Therapeutics Ltd about?
Antisense Therapeutics (ASX:ANP) is an Australian biotechnology company developing and commercialising antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc (NASDAQ:IONS), an established leader in antisense drug development. Antisense's flagship product is ATL1102, an antisense drug for the treatment of Duchenne muscular dystrophy (DMD). ATL1102 is currently in Phase 2b clinical trials, and it has the potential to be the first approved treatment for DMD. Antisense is also developing other antisense drugs for the treatment of rare diseases, including acromegaly, limb-girdle muscular dystrophy, and long COVID.
Antisense Therapeutics Ltd company media
Company Snapshot

Is Antisense Therapeutics Ltd a public or private company?


How many people does Antisense Therapeutics Ltd employ?


What sector is Antisense Therapeutics Ltd in?

Health Care

Where is the head office for Antisense Therapeutics Ltd?

Head Office
Victoria, Australia

What year was Antisense Therapeutics Ltd founded?

Year Founded
What does Antisense Therapeutics Ltd specialise in?
/Biotech /Pharmaceutical /Health /Medtech /Therapeutics
Icon representing a globe with map pin
Where does Antisense Therapeutics Ltd operate? Locations of Antisense Therapeutics Ltd global operations


  • Map pin icon
    Global view
  • Map pin icon
    Melbourne, Australia
Global operations world map
What are Antisense Therapeutics Ltd’s services?
Overview of Antisense Therapeutics Ltd offerings
ATL1102 for DMD: ATL1102 is a first-in-class antisense drug that has the potential to be the first approved treatment for DMD.
ATL1102 for long COVID: Antisense is investigating the potential of ATL1102 to treat long COVID, a post-COVID-19 condition that can cause a variety of symptoms, including fatigue, shortness of breath, and cognitive impairment.
ATL1102 for the treatment of Multiple Sclerosis.
ATL1103 for acromegaly: ATL1103 is an antisense drug in Phase 1 clinical trials for the treatment of acromegaly, a rare hormonal disorder that causes excessive growth.
Other projects: Antisense is also developing antisense drugs for the treatment of limb-girdle muscular dystrophy and other rare diseases.
Who is in the Antisense Therapeutics Ltd executive team?
Antisense Therapeutics Ltd leadership team
  • Mr. Mark  Diamond B.Sc., M.B.A., BSc, MBA, MAICD
    Mr. Mark Diamond B.Sc., M.B.A., BSc, MBA, MAICD
    CEO, MD & Director
  • Mr. Phillip Allen Hains BBus(Acc), CA, MBA
    Mr. Phillip Allen Hains BBus(Acc), CA, MBA
    CFO & Joint Company Sec.
  • Dr. George  Tachas
    Dr. George Tachas
    Director of Drug Discovery & Patents
  • Ms. Nuket  Desem
    Ms. Nuket Desem
    Director of Clinical and Regulatory affairs
  • Dr. Anthony  Filippis
    Dr. Anthony Filippis
    Chief Commercial Officer
  • Ms. Alicia  Mellors
    Ms. Alicia Mellors
    Joint Company Sec.